ADMINISTRATION OF ENCORAFENIB AND BINIMETINIB IN BRAF V600EMUTANTMALIGNANT MELANOMA. EFFICACY AND CLINICAL BEHAVIOR

Abstract

We present a clinical case of a 51-year-old patient with a primary ulcerated melanoma of the back (pT3b, Breslow 4 mm, BRAF V600E), diagnosed through radical excision and adjuvant immunotherapy with Pembrolizumab. Within 9 months, the patient developed disease progression, including two hepatic lesions with high metabolic activity and metastatic axillary lymph nodes. Based on the BRAF-mutant status and the aggressive clinical dynamics, first-line systemic drug therapy with Encorafenib and Binimetinib was administered. After five months of treatment, a complete metabolic response was observed. The case illustrates a real scenario of PD-1 resistance and demonstrates the high efficacy of BRAF/MEK inhibition.